Multiple Sclerosis Patents (Class 514/903)
  • Patent number: 9023402
    Abstract: Several classes of in vivo carbon monoxide-releasing compounds are useful for the treatment and/or prevention of diseases, such as chronic inflammatory, e.g., rheumatoid arthritis, and of diseases with a strong inflammatory component, such as atherosclerosis, stroke, coronary disease, and Alzheimers disease. The in vivo carbon monoxide-releasing compounds can be attached to known drug vectors and/or known anti-inflammatory drugs, such as aspirin.
    Type: Grant
    Filed: April 1, 2011
    Date of Patent: May 5, 2015
    Assignee: ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda.
    Inventors: Werner E. Haas, Carlos C. Romao, Beatriz Royo, Ana Cristina Fernandes, Isabel Goncalves
  • Patent number: 8936783
    Abstract: The present technology relates to the use of at least one strain of probiotic bacteria selected from Lactobacillus for the manufacture of a medicament for the treatment and/or prevention of an autoimmune disease.
    Type: Grant
    Filed: October 6, 2006
    Date of Patent: January 20, 2015
    Assignee: Probi AB
    Inventors: Jan Alenfall, Anna Berggren, Carola Rask, Agnes Wold, Shahram Aghaibeik-Lavasani
  • Patent number: 8916525
    Abstract: The present invention relates to TNFR2-TWEAKR fusion protein, more precisely to TNFR2-TWEAKR fusion protein acting as a double-antagonist to TNF-? and TWEAK, known as major causes of autoimmune arthritis which is one of autoimmune diseases. When the composition comprising TNFR2-TWEAKR fusion protein was treated to Th17 cells, the secretion of the inflammatory cytokine IL-17 was reduced but the secretion of the anti-inflammatory cytokine IL-10 generated in Treg cells was increased. Such effect of TNFR2-TWEAKR fusion protein was far greater than that of a single protein such as TNFR2-Fc or TWEAK-Fc. The TNFR2-TWEAKR fusion protein of the present invention has not only excellent treatment effect on arthritis in CIA mouse model not also excellent treatment effect on autoimmune rheumatoid arthritis by increasing the expression of Treg, the immune suppressive cells.
    Type: Grant
    Filed: March 18, 2011
    Date of Patent: December 23, 2014
    Assignees: Korea Research Institute of Bioscience and Biotechnology, Industry-Academic Cooperation Foundation, The Catholic University of Korea
    Inventors: Young Woo Park, Ki Won Jo, Srok Ho Yoo, Jung Yu, Dong Jin Kim, Sun-Ha Yoon, Eun Jung Song, Eun Kyung Lee, Jin Mi Oh, Kyu Won Cho, Mi La Cho, Ho Youn Kim, Mi Kyung Park, Hye Jwa Oh, Jin Sil Park, Yun Ju Woo, Jae Kyeong Byun, Jun Geol Ryu
  • Patent number: 8758770
    Abstract: Methods and compositions for the enteral treatment of autoimmune disease such a multiple sclerosis with polypeptide therapeutics. Enteral therapeutics comprise monomeric alpha-MSH polypeptides such as ACTH. Therapeutic formulations of the invention may be used to reduce the incidence or severity of autoimmune disease. For instance methods for the oral treatment of multiple sclerosis with alpha-MSH and ACTH are described.
    Type: Grant
    Filed: October 4, 2010
    Date of Patent: June 24, 2014
    Assignee: Research Development Foundation
    Inventor: Staley A. Brod
  • Patent number: 8741963
    Abstract: The present invention relates to the use of the S1P receptor modulator 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol, administered at a daily dosage of 0.5 mg, for inhibiting or treating neo-angiogenesis associated with multiple sclerosis.
    Type: Grant
    Filed: May 31, 2011
    Date of Patent: June 3, 2014
    Assignee: Novartis AG
    Inventors: Peter C. Hiestand, Christian Schnell
  • Patent number: 8741949
    Abstract: Carnitin-Palmitoyl-Transferase-1 (CPT-1) inhibitor for use in treating and/or preventing disorders caused by delipidation of neural tissue.
    Type: Grant
    Filed: June 25, 2009
    Date of Patent: June 3, 2014
    Assignee: Meta-IQ ApS
    Inventor: Josephus Dirk Nieland
  • Patent number: 8663685
    Abstract: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.
    Type: Grant
    Filed: July 20, 2011
    Date of Patent: March 4, 2014
    Assignee: Acorda Therapeutics, Inc.
    Inventors: Andrew R. Blight, Ron Cohen
  • Patent number: 8623861
    Abstract: The present invention relates to a method of treating demyelination diseases, such as multiple sclerosis, comprising administration of an atypical antipsychotic drug, such as quetiapine or an analog thereof, to a subject in need thereof.
    Type: Grant
    Filed: November 5, 2007
    Date of Patent: January 7, 2014
    Inventor: Xin-Min Li
  • Patent number: 8623408
    Abstract: Provided are compositions of cladribine and cyclodextrin which are especially suited for the oral and buccal administration of cladribine.
    Type: Grant
    Filed: September 27, 2010
    Date of Patent: January 7, 2014
    Assignee: Ares Trading S.A.
    Inventor: Nicholas S Bodor
  • Patent number: 8617536
    Abstract: This document provides methods and materials related to Prevotella histicola preparations. For example, Prevotella histicola preparations in the form of an oral medicament or dietary supplement (e.g., a pill, tablet, capsule) are provided. In addition, methods and materials for using a Prevotella histicola preparation provided herein as an anti-inflammatory agent are provided.
    Type: Grant
    Filed: October 27, 2010
    Date of Patent: December 31, 2013
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Joseph A. Murray, Eric V. Marietta, Susan H. Barton, Veena Taneja, Ashutosh Mangalam
  • Patent number: 8609730
    Abstract: This invention provides REL inhibitors which interfere with the DNA binding capacity of a REL protein. Additionally this invention provides methods of treating, abrogating, or preventing diseases which respond with a positive clinical score to a REL inhibitor. Methods of identifying REL inhibitor based on a REL protein three dimensional model are described.
    Type: Grant
    Filed: January 7, 2009
    Date of Patent: December 17, 2013
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Youhai H. Chen, Ramachandran Murali, Jing Sun
  • Patent number: 8551523
    Abstract: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.
    Type: Grant
    Filed: July 20, 2011
    Date of Patent: October 8, 2013
    Assignee: Acorda Therapeutics, Inc.
    Inventors: Andrew R. Blight, Ron Cohen
  • Patent number: 8524773
    Abstract: The present invention relates to the use of certain dialkyl fumarates for the preparation of pharmaceutical preparations for use in transplantation medicine or for the therapy of autoimmune diseases and said compositions in the form of micro-tablets or pellets. For this purpose, the dialkyl fumarates may also be used in combination with conventional preparations used in transplantation medicine and immunosuppressive agents, especially cyclosporines.
    Type: Grant
    Filed: September 12, 2012
    Date of Patent: September 3, 2013
    Assignee: Biogen Idec International GmbH
    Inventors: Rajendra Kumar Joshi, Hans-Peter Strebel
  • Patent number: 8440703
    Abstract: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at about 12 hours and the use of the composition to treat various neurological diseases, including multiple sclerosis. A method of selecting individuals based on responsiveness to a treatment, including, for example, identifying individuals who responded to treatment with a sustained release fampridine composition.
    Type: Grant
    Filed: November 18, 2011
    Date of Patent: May 14, 2013
    Assignee: Acorda Therapeutics, Inc.
    Inventors: Andrew R. Blight, Ron Cohen
  • Patent number: 8440704
    Abstract: This invention relates to a composition containing quercetin, vitamin B3, and vitamin C. Also disclosed is a method of using the composition for enhancing physical or mental performance or treating various diseases or disorders.
    Type: Grant
    Filed: December 16, 2009
    Date of Patent: May 14, 2013
    Assignee: Quercegen Pharmaceuticals LLC
    Inventor: Thomas Christian Lines
  • Patent number: 8435540
    Abstract: The present invention concerns methods and compositions for PEGylated complexes of defined stoichiometry and structure. Preferably, the PEGylated complex is formed using dock-and-lock technology, by attaching a therapeutic agent to a DDD sequence and a PEG moiety to an AD sequence, allowing the DDD sequence to bind to the AD sequence in a 2:1 stoichiometry, to form PEGylated complexes with two therapeutic agents and one PEG moiety. Alternatively, the therapeutic agent may be attached to the AD sequence and the PEG to the DDD sequence to form PEGylated complexes with two PEG moieties and one therapeutic agent. In more preferred embodiments, the therapeutic agent may comprise any peptide or protein of physiologic or therapeutic activity, preferably a cytokine, more preferably interferon-?2b. The PEGylated complexes exhibit a significantly slower rate of clearance when injected into a subject and are of use for treatment of a wide variety of diseases.
    Type: Grant
    Filed: March 6, 2012
    Date of Patent: May 7, 2013
    Assignee: IBC Pharmaceuticals, Inc.
    Inventors: Chien-Hsing Chang, David M. Goldenberg, William J. McBride, Edmund A. Rossi
  • Patent number: 8354437
    Abstract: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at about 12 hours and the use of the composition to treat various neurological diseases, including multiple sclerosis. A method of selecting individuals based on responsiveness to a treatment, including, for example, identifying individuals who responded to treatment with a sustained release fampridine composition.
    Type: Grant
    Filed: April 8, 2005
    Date of Patent: January 15, 2013
    Assignee: Acorda Therapeutics, Inc.
    Inventors: Andrew R. Blight, Ron Cohen
  • Patent number: 8313739
    Abstract: Methods for treating patients with cancer and autoimmune disorders using IL-28 and IL-29 molecules. The IL-28 and IL-29 molecules include polypeptides that have homology to the human IL-28 or IL-29 polypeptide sequence and proteins fused to a polypeptide with IL-28 and IL-29 functional activity. The molecules can be used as a monotherapy or in combination with other known cancer and/or autoimmune therapeutics.
    Type: Grant
    Filed: March 7, 2011
    Date of Patent: November 20, 2012
    Assignee: ZymoGenetics, Inc.
    Inventor: Paul O. Sheppard
  • Patent number: 8299120
    Abstract: The invention relates to a method of ameliorating multiple sclerosis and/or the symptoms of multiple sclerosis in a mammal, which comprises administering or having self administered to the mammal an effective amount of (a) cetyl myristate or (b) cetyl myristate and cetyl palmitate. In preferred embodiments the mode of administration is oral and both cetyl myristate and cetyl palmitate are administered.
    Type: Grant
    Filed: June 2, 2005
    Date of Patent: October 30, 2012
    Assignee: Lypanosis Pte Limited
    Inventors: Dianne Cadwallader, Timothy Meakin
  • Patent number: 8293796
    Abstract: The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein Z is OR1 or NR1R2 wherein each of R1 and R2 is independently H, or a hydrocarbyl group; X is an alkylene, alkenylene, or alkynylene group, each of which may be optionally substituted by one or more substituents selected from alkyl, COOH, CO2-alkyl, alkenyl, CN, NH2, hydroxy, halo, alkoxy, CF3 and nitro; Y is a polar functional group selected from OH, NO2, CN, COR3, COOR3, NR3R4, CONR3R4, SO3H, SO2—R3, SO2NR3R4 and CF3, where each of R3 and R4 is independently H or a hydrocarbyl group; A is an aryl or heteroaryl group, each of which may be optionally substituted; and B is (CH2)n where n is 0, 1, 2, 3, 4 or 5; with the proviso that: (i) when A is phenyl, n is 0, and Z is OH, X—Y is other than meta-C?—C—(CH2)2CO2H, meta-C?—C—(CH2)2OH, meta-C?C—(CH2)2CO2Me, meta-(CH2)4CO2H, ortho-CH2CO2H, ortho-(CH2)2CO2H and ortho-(CH2)4CO2H; and (ii) when A is phenyl, n is 0, and Z is OMe, X—Y is other than meta-C?
    Type: Grant
    Filed: February 18, 2010
    Date of Patent: October 23, 2012
    Assignee: University College London
    Inventors: Masahiro Okuyama, David Selwood, Cristina Visintin, David Baker, Gareth Pryce
  • Patent number: 8231874
    Abstract: Method of treating autoimmune conditions are disclosed comprising administering to a mammalian subject IL-12 or an IL-12 antagonist. In certain preferred embodiments the autoimmune condition is one which is promoted by an increase in levels of IFN-? or TNF-?. Suitable conditions for treatment include multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes melitis and autoimmune inflammatory eye disease.
    Type: Grant
    Filed: July 28, 2011
    Date of Patent: July 31, 2012
    Inventors: John Leonard, Samuel Goldman, Richard O'Hara, Jr.
  • Patent number: 8188152
    Abstract: Use of a compound for the manufacture of a medicament for use in therapy of a neurodegenerative condition, wherein the compound is of formula (I): wherein R1 is CHR4—OR5 or CHR4—SR5, or aryl or heteroaryi optionally substituted with one or more groups R6; R2 is alkyl or is part of a ring with R3; R3 is H, alkyl or CH2 (when forming part of a ring with R2); R4 is H or alkyl or is part of a ring with R 5; R5 is aryl or heteroaryi optionally substituted with R7; each R6 is independently alkyl, CF3, OH, Oalkyl, OCOalkyl, CONH2, CN, halogen, NH2, NO2, NHCHO, NHCONH2, NHSO2alkyl, CONH2, SOMe, SO2NH2, Salkyl, CH2SO2alkyl or OCONalkyl2; R7 is R8 or (CH2)nOR8, R9, CF3, OH, OR9, OCOR9, COR9, COOR9, CONH2, CH2CONH2, CN, halogen, NH2, NO2, NHCHO, NHCONH2, NHCONHR7, NHCON(R9)2, NHCOR9, NHCOaryl, NHSO2Me, CONH2, SMe, SOMe or SO2NH2; R8 is (CH2)nOR9, (CH)nOR9, (CH2)nCOOR9 or (CH2)nCOaryl; R9 is alkyl or cycloalkyl; and n is 1 to 4; or a salt thereof.
    Type: Grant
    Filed: September 21, 2006
    Date of Patent: May 29, 2012
    Assignee: Biocopea Limited
    Inventors: Robin Mark Bannister, Michael Harvey Lyne
  • Patent number: 8129383
    Abstract: There is disclosed dosage forms and methods for treating a patient with an inflammatory disorder with a therapeutically effective amount of aminopterin, or a pharmaceutically acceptable salt thereof, that achieve efficacy without concomitant toxicity. Specifically, there is disclosed a method for treating an inflammatory disorder in a patient with uninterrupted doses of aminopterin.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: March 6, 2012
    Assignee: Aminopterin LLC
    Inventors: John Zebala, Barton A. Kamen
  • Patent number: 8088755
    Abstract: 11a,12-dehydrotetracycline compounds are described.
    Type: Grant
    Filed: February 6, 2006
    Date of Patent: January 3, 2012
    Assignee: Paratek Pharmaceuticals, Inc.
    Inventors: Joel Berniac, Mohamed Y. Ismail, Mark L. Nelson, Faye Seyedi
  • Patent number: 8080540
    Abstract: Estratrien-triazoles corresponding to formula (I) (shown below) which are useful in therapy, especially for the treatment and/or prevention or inhibition of a steroid hormone dependent disorder, preferably a steroid hormone dependent disease or disorder requiring the inhibition of a 17?-hydroxysteroid dehydrogenase (17?-HSD) such as 17?-HSD type 1, type 2 or type 3 enzyme.
    Type: Grant
    Filed: September 18, 2007
    Date of Patent: December 20, 2011
    Assignee: Abbott Products GmbH
    Inventors: Josef Messinger, Uwe Schoen, Heinrich-Hubert Thole, Bettina Husen, Pasi Koskimies, Lila Kallio nee Pirkkala
  • Patent number: 8012475
    Abstract: Method of treating autoimmune conditions are disclosed comprising administering to a mammalian subject IL-12 or an IL-12 antagonist. In certain preferred embodiments the autoimmune condition is one which is promoted by an increase in levels of IFN-? or TNF-?. Suitable conditions for treatment include multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes melitis and autoimmune inflammatory eye disease.
    Type: Grant
    Filed: May 14, 2009
    Date of Patent: September 6, 2011
    Assignee: Genetics Institute, LLC
    Inventors: John Leonard, Samuel Goldman, Richard O'Hara, Jr.
  • Patent number: 7964220
    Abstract: Several classes of in vivo carbon monoxide-releasing compounds are useful for the treatment and/or prevention of diseases, such as chronic inflammatory, e.g., rheumatoid arthritis, and of diseases with a strong inflammatory component, such as atherosclerosis, stroke, coronary disease, and Alzheimers disease. The in vivo carbon monoxide-releasing compounds can be attached to known drug vectors and/or known anti-inflammatory drugs, such as aspirin.
    Type: Grant
    Filed: June 14, 2006
    Date of Patent: June 21, 2011
    Assignee: ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda.
    Inventors: Werner E. Haas, Carlos C. Romao, Beatriz Royo, Ana Cristina Fernandes, Isabel Goncalves
  • Patent number: 7951371
    Abstract: This invention relates to compositions and methods comprising “lymphotoxin-?-receptor blocking agents”, which block lymphotoxin-? receptor signalling. Lymphotoxin-? receptor blocking agents are useful for treating lymphocyte-mediated immunological diseases, and more particularly, for inhibiting Th1 cell-mediated immune responses. This invention relates to soluble forms of the lymphotoxin-?.receptor extracellular domain that act as lymphotoxin-? receptor blocking agents. This invention also relates to the use of antibodies directed against either the lymphotoxin-?. receptor or its ligand, surface lymphotoxin, that act as lymphotoxin-? receptor blocking agents. A novel screening method for selecting soluble receptors, antibodies and other agents that block LT-? receptor signalling is provided.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: May 31, 2011
    Assignee: Biogen Idec MA Inc.
    Inventors: Jeffrey L. Browning, Christopher D. Benjamin, Paula S. Hochman
  • Patent number: 7923440
    Abstract: A method of treating or preventing an immune mediated disorder in a mammal, said method comprising the administration of a therapeutically effective amount of an estrogenic component to said mammal, wherein the estrogenic component is selected from the group consisting of: substances represented by the following formula: in which formula R1, R2, R3, R4 independently are a hydrogen atom, a hydroxyl group or an alkoxy group with 1-5 carbon atoms; each of R5, R6, R7 is a hydroxyl group; no more than 3 of R1, R2, R3, R4 are hydrogen atoms; precursors capable of liberating a substance according to the aforementioned formula when used in the present method; and mixtures of one or more of the aforementioned substances and/or precursors. Another aspect of the invention relates to a pharmaceutical formulation comprising the aforementioned estrogenic component, an immunotherapeutic agent and a pharmaceutically acceptable excipient.
    Type: Grant
    Filed: June 11, 2003
    Date of Patent: April 12, 2011
    Assignee: Pantarhei Bioscience B.V.
    Inventors: Evert Johannes Bunschoten, Herman Jan Tijmen Coelingh Bennink, Christian Franz Holinka
  • Patent number: 7883703
    Abstract: The invention provides novel methods of administering anti-CD3 antibodies, e.g., via oral or mucosal delivery. The invention also provides methods of treating, preventing, or delaying the onset of autoimmune disorders by oral or mucosal administration of anti-CD3 antibodies. Finally, the invention provides compositions including anti-CD3 antibodies, suitable for oral or mucosal administration.
    Type: Grant
    Filed: November 12, 2004
    Date of Patent: February 8, 2011
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Howard L. Weiner, Mohamed H. Sayegh
  • Patent number: 7812029
    Abstract: The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds, as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Specific examples of autoimmune diseases that can be treated or prevented with the compounds include rheumatoid arthritis and/or its associated symptoms, systemic lups erythematosis and/or its associated symptoms and multiple sclerosis and/or its associated symptoms.
    Type: Grant
    Filed: February 8, 2008
    Date of Patent: October 12, 2010
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Rajinder Singh, Ankush Argade, Donald G. Payan, Jeffrey Clough, Holger Keim, Somasekhar Bhamidipati, Catherine Sylvain, Hui Li
  • Patent number: 7803840
    Abstract: The present invention relates to the use of certain dialkyl fumarates for the preparation of pharmaceutical preparations for use in transplantation medicine or for the therapy of autoimmune diseases and said compositions in the form of micro-tablets or pellets. For this purpose, the dialkyl fumarates may also be used in combination with conventional preparations used in transplantation medicine and immunosuppressive agents, especially cyclosporines.
    Type: Grant
    Filed: March 17, 2009
    Date of Patent: September 28, 2010
    Assignee: Biogen Idec International GmbH
    Inventors: Rajendra Kumar Joshi, Hans-Peter Strebel
  • Patent number: 7641901
    Abstract: Antibodies that bind with a B-cell antigen provide an effective means to treat autoimmune disorders. Antibodies and fragments, which may be conjugated or naked, are used alone or in multimodal therapies. The antibodies may be bispecific antibodies which may be produced recombinantly as fusion proteins, or as hybrid, polyspecific antibodies.
    Type: Grant
    Filed: September 12, 2005
    Date of Patent: January 5, 2010
    Assignee: Immunomedics, Inc.
    Inventors: David M. Goldenberg, Hans J. Hansen
  • Patent number: 7619001
    Abstract: The present invention relates to the use of certain dialkyl fumarates for the preparation of pharmaceutical preparations for use in transplantation medicine or for the therapy of autoimmune diseases and said compositions in the form of micro-tablets or pellets. For this purpose, the dialkyl fumarates may also be used in combination with conventional preparations used in transplantation medicine and immunosuppressive agents, especially cyclosporines.
    Type: Grant
    Filed: June 20, 2007
    Date of Patent: November 17, 2009
    Assignee: Biogen IDEC International GmbH
    Inventors: Rajendra Kumar Joshi, Hans-Peter Strebel
  • Patent number: 7612183
    Abstract: The present invention relates to altered antibodies to myelin associated glycoprotein (MAG), pharmaceutical formulations containing them and to the use of such antibodies in the treatment and/or prophylaxis of neurological diseases/disorders.
    Type: Grant
    Filed: August 5, 2003
    Date of Patent: November 3, 2009
    Assignee: Glaxo Group Limited
    Inventors: Jonathan Henry Ellis, Volker Germaschewski
  • Patent number: 7541338
    Abstract: Disclosed is the characterization and purification of DNA encoding a numerous polypeptides useful for the stimulation of glial cell (particularly, Schwann cell) mitogenesis and treating glial cell tumors. Also disclosed are DNA sequences encoding novel polypeptides which may have use in stimulating glial cell mitogenesis and treating glial cell tumors. Methods for the synthesis, purification and testing of both known and novel polypeptides for their use as both therapeutic and diagnostic aids in the treatment of diseases involving glial cells are also provided. Methods are also provided for the use of these polypeptides for the preparation of antibody probes useful for both diagnostic and therapeutic use in diseases involving glial cells.
    Type: Grant
    Filed: July 30, 2007
    Date of Patent: June 2, 2009
    Assignees: Acorda Therapeutics, Inc., Ludwig Institute for Cancer Research
    Inventors: Andrew Goodearl, Paul Stroobant, Luisa Minghetti, Michael Waterfield, Mark Marchioni, Mario Su Chen, Ian Hiles
  • Patent number: 7534803
    Abstract: N-(Pyridinyl)-1H-indol-1-amines of formula I provide a unique combination of blocking properties for both the potassium and sodium channels. These compounds are useful for the treatment of Demyelinating Diseases and Conditions such as Multiple Sclerosis, Spinal Cord Injury, Traumatic Brain Injury and Stroke. The compounds are also useful for Stroke Rehabilitation, the treatment of Bladder Irritation and Dysfunction, and the treatment of Neuropathic Pain and Chemokine-Induced Pain.
    Type: Grant
    Filed: September 27, 2005
    Date of Patent: May 19, 2009
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Craig P. Smith, Michel P. Rathbone, Margaret Petty, David Rampe
  • Patent number: 7534430
    Abstract: Method of treating autoimmune conditions are disclosed comprising administering to a mammalian subject IL-12 or an IL-12 antagonist. In certain preferred embodiments the autoimmune condition is one which is promoted by an increase in levels of IFN-? or TNF-?. Suitable conditions for treatment include multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes melitis and autoimmune inflammatory eye disease.
    Type: Grant
    Filed: September 28, 2006
    Date of Patent: May 19, 2009
    Assignee: Genetics Institute, LLC
    Inventors: John Leonard, Samuel Goldman, Richard O'Hara, Jr.
  • Patent number: 7531575
    Abstract: Described is a rational design of therapeutic and/or prophylactic methods of treating conditions characterized by aberrant or otherwise unwanted microglial cell functioning and rational design methods for treating a range of neurological disorders which are characterized by nitric oxide induced neuronal damage.
    Type: Grant
    Filed: October 31, 2003
    Date of Patent: May 12, 2009
    Assignee: Eberhard-Karls-Universität Tübingin
    Inventors: Michael Weller, Wolfgang Wick, Jörg Wischhusen, Michael Platten
  • Patent number: 7517886
    Abstract: The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds, as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Specific examples of autoimmune diseases that can be treated or prevented with the compounds include rheumatoid arthritis and/or its associated symptoms, systemic lups erythematosis and/or its associated symptoms and multiple sclerosis and/or its associated symptoms.
    Type: Grant
    Filed: July 29, 2003
    Date of Patent: April 14, 2009
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Rajinder Singh, Ankush Argade, Donald G. Payan, Jeffrey Clough, Holger Keim, Somasekhar Bhamidipati, Catherine Sylvain, Hui Li
  • Patent number: 7456158
    Abstract: The present invention provides new chemically modified 4-dedimethylaminotetracycline compounds that can be substituted with aryl, alkenyl, or alkynyl groups. The 7, 8, and/or 9 positions and methods for preparing such compounds. Other tetracycline compounds include the 4-dedimethylaminotetracycline derivatives with an oxime group, NH-Alkyl, or N—NH-Alkyl group substituted at the C4 position as well as C2 Mannich derivatives. The present invention also provides a method of treating a mammal suffering from conditions or diseases by administering to the mammal an effective amount of the new chemically modified tetracycline compounds.
    Type: Grant
    Filed: January 5, 2005
    Date of Patent: November 25, 2008
    Assignee: Galderma Laboratories, Inc.
    Inventors: Robert Ashley, Joseph J. Hlavka
  • Patent number: 7425332
    Abstract: The present invention is directed to polypeptides containing at least three amino acids randomly joined in a linear array; wherein at least one of the three amino acids is an aromatic amino acid, at least one of the three amino acids is a charged amino acid and at least one amino acid is an aliphatic amino acid. In a preferred embodiment the polypeptide contains three or four of the following amino acids: tyrosine, alanine, glutamic acid or lysine. According to the present invention, the present polypeptides bind to antigen presenting cells, purified human lymphocyte antigens (HLA) and/or Copolymer 1-specific T cells. Moreover, according to the present invention, these polypeptides can be formulated into pharmaceutical compositions for treating autoimmune disease. The present invention further contemplates methods of treating an autoimmune disease in a mammal by administering a pharmaceutically effective amount of any one of the present polypeptides to the mammal.
    Type: Grant
    Filed: September 27, 2006
    Date of Patent: September 16, 2008
    Assignees: Yeda Research and Development Co., Ltd., President and Fellows of Harvard University
    Inventors: Michael Sela, Masha Fridkis-Hareli, Jack L. Strominger, Rina Aharoni, Dvora Teitelbaum, Ruth Arnon
  • Patent number: 7423011
    Abstract: The invention provides a variety of therapeutic uses for CXCR4 antagonists. In various embodiments, CXCR4 antagonists may be used as therapeutically as follows, or to manufacture a medicament for such therapeutic treatments: reducing interferon gamma production by T-cells, treatment of an autoimmune disease, treatment multiple sclerosis, treatment of cancer, inhibition of angiogenesis. The invention provides corresponding methods of medical treatment, in which a therapeutic dose of a CXCR4 antagonist is administered in a pharmacologically acceptable formulation. Accordingly, the invention also provides therapeutic compositions comprising a CXCR4 antagonist and a pharmacologically acceptable excipient or carrier. The CXCR4 antagonists for use in the invention may be peptide compounds comprising a substantially purified peptide fragment, modified fragment, analogue or pharmacologically acceptable salt of SDF-1.
    Type: Grant
    Filed: May 23, 2005
    Date of Patent: September 9, 2008
    Assignee: The University of British Columbia
    Inventors: Ian Clark-Lewis, Jiang-Hong Gong, Vincent Duronio
  • Patent number: 7357925
    Abstract: PEG-IFN-? conjugates, where a PEG moiety is covalently bound to Cys17 of human IFN-?, are produced by a process of site specific PEGylation with a thiol reactive PEGylating agent. A pharmaceutical composition and a method for treating infections, tumors and autoimmune and inflammatory diseases are also provided. The invention further relates to a method for the stepwise attachment of PEG moieties in series to a polypeptide, and more particularly to IFN-?.
    Type: Grant
    Filed: August 28, 2003
    Date of Patent: April 15, 2008
    Assignee: Laboratoires Seronosa
    Inventors: Nabil El-Tayar, Michael J. Roberts, Milton Harris, Wayne Sawlivich
  • Patent number: 7285531
    Abstract: The invention involves prophylaxis or treatment of nervous system pathological conditions. This is accomplished by administering secretable glial growth factors, such as the molecule referred to as GGF-2.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: October 23, 2007
    Assignees: Acorda Therapeutics, Inc., Ludwig Institute for Cancer Research
    Inventors: Andrew Goodearl, Paul Stroobant, Luisa Minghetti, Michael Waterfield, Mark Marchioni, Mario Su Chen, Ian Hiles
  • Patent number: 7256184
    Abstract: A method for the treatment and prophylaxis of conditions of aging in humans, such conditions of aging associated with a decreased presence of one or more cell-specific carbonic anhydrase enzymes. Such conditions include chronic neurodegenerative conditions including dementia such as Alzheimer's disease. The method comprises administering to the patient a pharmaceutically effective, non-toxic amount of a compound that increases the presence of one or more cell-specific carbonic anhydrase enzymes whose levels are reduced in the patient. Such compound may be the cell-specific carbonic anhydrase enzyme, a compound that when absorbed by the body reacts or dissociates to form the cell-specific carbonic anhydrase enzyme, or a compound that promotes the natural generation of the cell-specific carbonic anhydrase enzyme within the body.
    Type: Grant
    Filed: June 1, 2004
    Date of Patent: August 14, 2007
    Inventor: Victorio C. Rodriguez
  • Patent number: 7235590
    Abstract: The invention relates to the use of treosulfan and/or derivatives thereof for producing a pharmaceutical composition used in the treatment of multiple sclerosis.
    Type: Grant
    Filed: August 12, 2003
    Date of Patent: June 26, 2007
    Assignee: Medac Gesellschaft fur Klinische Spezialpraparate mbH
    Inventor: Gretel Sass
  • Patent number: 7230015
    Abstract: N-(Pyridinyl)-1H-indol-1-amines of formula I provide a unique combination of blocking properties for both the potassium and sodium channels. These compounds are useful for the treatment of Demyelinating Diseases and Conditions such as Multiple Sclerosis, Spinal Cord Injury, Traumatic Brain Injury and Stroke. The compounds are also useful for Stroke Rehabilitation, the treatment of Bladder Irritation and Dysfunction, and the treatment of Neuropathic Pain and Chemokine-Induced Pain.
    Type: Grant
    Filed: March 14, 2005
    Date of Patent: June 12, 2007
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Craig P Smith, Michel P Rathbone, Margaret Petty, David Rampe
  • Patent number: 7179821
    Abstract: N-(Pyridinyl)-1H-indol-1-amines of formula I provide a unique combination of blocking properties for both the potassium and sodium channels. These compounds are useful for the treatment of Demyelinating Diseases and Conditions such as Multiple Sclerosis, Spinal Cord Injury, Traumatic Brain Injury and Stroke. The compounds are also useful for Stroke Rehabilitation, the treatment of Bladder Irritation and Dysfunction, and the treatment of Neuropathic Pain and Chemokine-Induced Pain.
    Type: Grant
    Filed: March 14, 2005
    Date of Patent: February 20, 2007
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Craig P Smith, Michel P Rathbone, Margaret Petty, David Rampe
  • Patent number: 7141558
    Abstract: Biologically active 19-nor vitamin D analogs substituted at C-2 in the A-ring with an ethylidene or an ethyl group. These compounds have preferential activity on mobilizing calcium from bone and either high or normal intestinal calcium transport activity which allows their in vivo administration for the treatment of metabolic bone diseases where bone loss is a major concern. These compounds are also characterized by high cell differentiation activity.
    Type: Grant
    Filed: July 28, 2005
    Date of Patent: November 28, 2006
    Assignee: Wiscousin Alumni Research Foundation
    Inventors: Hector F. DeLuca, Rafal R. Sicinski